Overview

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

Status:
Completed
Trial end date:
2021-09-16
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
Phase:
Phase 2
Details
Lead Sponsor:
Alkahest, Inc.
Treatments:
Aflibercept